How has been the historical performance of Marksans Pharma?

Answer:The historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years.

Breakdown:
Marksans Pharma has demonstrated significant growth in net sales, increasing from 1,134.21 Cr in March 2020 to 2,622.85 Cr in March 2025. This upward trend is reflected in total operating income, which rose from 1,000.07 Cr in March 2019 to 2,622.85 Cr in March 2025. The company's total expenditure has also increased, reaching 2,090.16 Cr in March 2025, up from 941.96 Cr in March 2020. Operating profit, excluding other income, has shown a positive trend, climbing from 192.25 Cr in March 2020 to 532.69 Cr in March 2025. Profit before tax has similarly risen from 157.17 Cr in March 2020 to 503.97 Cr in March 2025, while profit after tax increased from 120.75 Cr to 382.62 Cr during the same period. The earnings per share (EPS) has improved significantly, from 2.95 in March 2020 to 8.4 in March 2025. On the balance sheet, total assets grew from 902.03 Cr in March 2020 to 3,239.63 Cr in March 2025, with total liabilities also increasing from 902.03 Cr to 3,239.63 Cr. The cash flow from operating activities has been positive, although it decreased from 230.00 Cr in March 2024 to 206.00 Cr in March 2025. Overall, Marksans Pharma's financial performance reflects robust growth and improved profitability over the years.